Production (Stage)
Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 41.01% | 119.19% | 179.79% | 283.69% | 287.79% |
| Gross Profit | -41.01% | -119.19% | -179.79% | -283.69% | -287.79% |
| SG&A Expenses | 1.74% | 21.77% | 62.57% | 91.12% | 84.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.35% | 77.33% | 126.70% | 187.84% | 171.13% |
| Operating Income | -26.35% | -77.33% | -126.70% | -187.84% | -171.13% |
| Income Before Tax | -37.19% | -74.59% | -96.21% | -79.37% | -91.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.59% | -74.59% | -96.14% | -79.30% | -91.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.59% | -74.59% | -96.14% | -79.30% | -91.57% |
| EBIT | -26.35% | -77.33% | -126.70% | -187.84% | -171.13% |
| EBITDA | -26.32% | -77.27% | -126.96% | -191.92% | -179.29% |
| EPS Basic | -13.32% | -33.16% | -2.37% | 24.49% | 29.35% |
| Normalized Basic EPS | 2.16% | -16.36% | -25.16% | 0.65% | 9.05% |
| EPS Diluted | -13.32% | -33.16% | -2.37% | 24.49% | 29.35% |
| Normalized Diluted EPS | 2.16% | -16.36% | -25.16% | 0.65% | 9.05% |
| Average Basic Shares Outstanding | 22.95% | 32.84% | 64.37% | 129.33% | 174.86% |
| Average Diluted Shares Outstanding | 22.95% | 32.84% | 64.37% | 129.33% | 174.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |